Thromb Haemost 1975; 33(02): 230-243
DOI: 10.1055/s-0038-1647877
Original Article
Schattauer GmbH

The Inhibition of Urokinase by Aromatic Diamidines

J. D Geratz
1   Department of Pathology University of North Carolina School of Medicine Chapel Hill, North Carolina 27514
,
Michael C.-F Cheng
1   Department of Pathology University of North Carolina School of Medicine Chapel Hill, North Carolina 27514
› Author Affiliations
Further Information

Publication History

Received 17 September 1974

Accepted 12 December 1974

Publication Date:
02 July 2018 (online)

Summary

1. Structure-activity relationships have been established for the inhibition of urokinase by aromatic diamidines. In an assay system employing purified urokinase and human plasminogen the most potent inhibitor was found in 4′,4″-diamidino-2-hydroxy-1,4-diphenoxybutane which proved 5600 times more active on a molar basis than epsilon-aminocaproic acid (E-ACA).

2. 4′4″-diamidino-2-hydroxy-1,4-diphenoxybutane behaved as a competitive inhibitor of the urokinase catalyzed hydrolysis of Nα-acetyl-L-lysine methyl ester. At pH 7.85 and 37° C the Ki value was determined as 3.18 × 10–6 M which compares with a value of 6.79 × 10–5 M for p-aminobenzamidine and 3.57 × 10–2 M for E–ACA.

3. In two fibrinolytic tests including urokinase as activator the superiority of diamidines over E–ACA was less marked than in the pure plasminogen activation system. This was due to the presence of certain plasma proteins in the fibrinolysis assays which augmented the inhibitory strength of E-ACA. The order of effectiveness of diamidines in the lysis tests was also different from the one in the activation test. In a human fibrin clot lysis test the most active inhibitor was 3′3″-diamidino-2-hydroxy-1,4-diphenoxybutane which was 1700 times more effective on a molar basis than E-ACA. In a human plasma clot lysis test the strongest inhibitor, 2-hydroxy-stilbamidine, was 70 times more powerful than E–ACA.

 
  • References

  • 1 Abiko Y, Iwamoto M, Tomikawa M. Plasminogen-plasmin system. V. A stoichiometric equilibrium complex of plasminogen and a synthetic inhibitor. Biochimica et Biophysica Acta 1969; 185: 424
  • 2 Abiko Y, Iwamoto M. Plasminogen-plasmin system VII. Potentiation of antifibrinolytic action of a synthetic inhibitor, tranexamic acid, by A2-macroglobulin antiplasmin. Biochimica et Biophysica Acta 1970; 214: 411
  • 3 Ashley J. N, Barber H. J, Ewins A. J, Newbery G, Self A. D. H. A chemotherapeutic comparison of the trypanocidal action of some aromatic diamidines. Journal of the Chemical Society 1942; 103
  • 4 Berg S. S, Newbery G. The search for chemotherapeutic amidines Part X. Substituted 4:4’-diamidino-A, ω-diphenoxyalkanes and -diphenyl ethers.. Journal of the Chemical Society 1949: 642
  • 5 Brockway W, Castellino F. Measurement of the binding of antifibrinolytic amino acids to various plasminogens. Archives of Biochemistry and Biophysics 1972; 151: 194
  • 6 Claeys H, Vermylen J. Physicochemical and proenzyme properties of NH2-terminal glutamic acid and NH2-terminal lysine human plasminogen. Influence of B-aminohexanoic acid. Biochimica et Biophysica Acta 1974; 342: 351
  • 7 Dixon M. The determination of enzyme inhibitor constants. Biochemical Journal 1953; 55: 170
  • 8 Geratz J. D. Inhibition of thrombin, plasmin and plasminogen activation by amidino compounds. Thrombosis et Diathesis Haemorrhagica 1970; 23: 486
  • 9 Geratz J. D. Inhibition of coagulation and fibrinolysis by aromatic amidino compounds. An in vitro and in vivo study. Thrombosis et Diathesis Haemorrhagica 1971; 25: 391
  • 10 Geratz J. D. Structure-activity relationships for the inhibition of plasmin and plasminogen activation by aromatic diamidines and a study of the effect of plasma proteins on the inhibition process. Thrombosis et Diathesis Haemorrhagica 1973; 29: 154
  • 11 Geratz J. D, Cheng M. C. F, Tidwell R. R. New aromatic diamidines with central a-oxyalkane or A,ω-dioxyalkane chains. Structure-activity relationships for the inhibition of trypsin, pancreatic kallikrein and thrombin and for the inhibition of the overall coagulation process.. Journal of Medicinal Chemistry (in press) 1975
  • 12 Geratz J. D, Whitmore A. C, Cheng M. C. F, Piantadosi C. Diamidino- α, ω-diphenoxyalkanes. Structure-activity relationships for the inhibition of thrombin, pancreatic kallikrein, and trypsin. Journal of Medicinal Chemistry 1973; 16: 970
  • 13 Heimburger N, Schwick G. Die Fibrinagar-Elektrophorese. 2. Mitteilung: Untersuchungen zum Wirkungsmechanismus der Streptokinase. Thrombosis et Diathesis Haemorrhagica 1962; 7: 444
  • 14 Siegelman A. M, Carlsen A. S, Robertson T. Investigation of serum trypsin and related substances. 1. The quantitative demonstration of trypsinlike activity in human serum by a micromethod. Archives of Biochemistry and Biophysics 1962; 97: 159
  • 15 Thorsen S, Astrup T. Biphasic inhibition of urokinase-induced fibrinolysis by E-aminocaproic acid, distinction from tissue plasminogen activator. Proceedings of the Society for Experimental Biology and Medicine 1969; 130: 811
  • 16 Walther P. J, Steinman H. M, Hill R. L, McKee P. A. Activation of human plasminogen by urokinase. Partial characterization of a pre-activation peptide. Journal of Biological Chemistry 1974; 249: 1173
  • 17 Walton P. L. The hydrolysis of A-N-acetylglycyl-L-lysine methyl ester by urokinase. Biochimica et Biophysica Acta 1967; 132: 104
  • 18 Wiman B. Primary structure of peptides released during activation of human plasminogen by urokinase. European Journal of Biochemistry 1973; 39: 1